Navigation Links
U.S. Blood Centers Pursue an Evolving Role in Cell Therapies
Date:9/26/2013

Providence, RI (PRWEB) September 26, 2013

As part of its national strategy to involve blood centers in the production and delivery of cell therapies to U.S. patients, Blood Centers of America, Inc. (BCA) announced today it will play a leadership role in representing North American independent blood centers at the upcoming two-day Stem Cells & Regenerative Medicine Congress hosted by Terrapinn starting September 30th in Cambridge, M.A.

In addition to showcasing BCA member capabilities in the event's tradeshow, BCA will be hosting one-on-one and networking meetings with senior executives of leading cell therapy and cell-based immunotherapy companies.

"The independent blood centers comprising BCA member-owners believe in a future in which they are an important partner in the preparation and delivery of cell therapies to patients,” stated BCA CEO, Bill Block. “Blood centers are a critical part of the nation’s healthcare system and cell therapy represents the next wave of healthcare innovation that we can and will support from critical biological collections, to cell processing, product manufacturing, and even administration of the products to patients.”

"BCA is a network of centers geographically dispersed throughout North America,” cites Lisa Shaffer, BCA’s Vice President of Contracts & Business Development, “with considerable experience in collecting, processing and distributing regulatory-compliant, clinical-grade biological materials. We are actively engaging cell therapy leadership in a discussion about how we can leverage BCA member infrastructure and capabilities in the development and processing of cell therapy products and their safe and cost-effective delivery to patients."

About BCA
BCA is a member-owned organization comprised of 41 independent blood centers geographically dispersed throughout the North America, providing more than 48% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, BCA members provide a myriad of other services in cell therapies, blood management, therapeutic apheresis, tissue and cord blood banking, etc.

BCA provides thousands of units of biological materials to life science researchers, clinicians, therapeutic companies, or companies doing medical device, diagnostic or therapeutic development work.

BCA assists cell therapy companies with securing reliable and compliant sources for the cells used in their therapeutic products and/or pre-clinical research. Where a client need exceeds the capacity of a single center, BCA can assist with putting in place a multi-center supply agreement around cell collections, processing, storage or other handling.

In 2012, BCA generated over $6 million in custom products and services to cell therapy companies including patient-donor collections for autologous cell therapies in clinical trial and commercial distribution.

For more information about BCA and its services, see http://www.bca.coop.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11159274.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Blood Centers of America Experiences Record Growth
2. Miami’s Preferred Cord Blood Laboratory, GeneCell International, Partakes in North Shore Medical Center and Hialeah Hospital’s OB/GYN Symposium
3. Blood Test on the Horizon to Detect Aortic Aneurysm and Aortic Dissection
4. Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test to Identify Cancer Patients at Risk of Death by Infection after Cord Blood Transplants
5. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
6. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
7. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
8. ResearchMoz.us: RFID Blood Monitoring Systems (Blood Refrigerators and Freezers) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
9. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
10. BCA Announces a New Member Joins Its Blood Center Coperative
11. New target for the fight against cancer as a result of excessive blood vessel formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):